VCELVericel Ord
About Vericel Ord
Vericel (NASDAQ:VCEL) specializes in developing, manufacturing, and marketing autologous cell-based therapies for patients with serious diseases and conditions. Their operations focus on creating treatments that support the body's ability to heal itself. Vericel's projects primarily revolve around therapies for cartilage defects in the knee, severe burns, and various other conditions that require regenerative medicine solutions. One of their primary objectives is to deliver innovative and effective cell therapy products to patients in need, aiming to improve the quality of life for those suffering from these serious medical issues. The company dedicates itself to advancing the field of regenerative medicine through ongoing research and development efforts.
What is VCEL known for?
Snapshot
Public US
Ownership
1989
Year founded
342
Employees
Cambridge, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Newton, US
Produtos e/ou serviços de Vericel Ord
- MACI (autologous cultured chondrocytes on porcine collagen membrane) for repairing symptomatic, single or multiple cartilage defects of the knee.
- Epicel (cultured epidermal autografts) for treating patients with deep dermal or full-thickness burns comprising a large total body surface area.
- Nexobrid (a bromelain-based topical solution) for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
- Carticel (autologous cultured chondrocytes) for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma.
- Laviv (Azficel-T), an autologous cellular product for improving the appearance of moderate to severe nasolabial fold wrinkles in adults.
- Participation in research and development for new regenerative therapies and solutions in orthopedics and burn care, aiming to expand their product portfolio.
equipe executiva do Vericel Ord
- Mr. Dominick C. Colangelo Esq.CEO, President & Director
- Mr. Joseph Anthony Mara Jr.CFO & Treasurer
- Mr. Michael HalpinChief Operating Officer
- Mr. Sean C. FlynnChief Legal Officer
- Ms. Karen MahoneyChief Human Resources Officer
- Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.Chief Medical Officer
- Mr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate Controller
- Mr. Eric BurnsVice President of Finance & Investor Relations
- Mr. Roland DeAngelisChief Marketing Officer
- Mr. Patrick J. FowlerSenior Vice President of Corporate Development & Strategy